Ronnie DePue, PharmD

Axsome Therapeutics Inc. New York, NY, USA

Poster(s):

• (56) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
  Wednesday, October 29, 2025

• (134) Budget impact of Symbravo® (MoSEIC™ meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults
  Wednesday, October 29, 2025